An observational study examining bioactive substances and genetic polymorphism for personalized pharmacotherapy in hyperlipidemia

An observational study examining bioactive substances and genetic polymorphism for personalized pharmacotherapy in hyperlipidemia - Examination of bioactive substances and genetic polymorphism for personalized pharmacotherapy in hyperlipidemia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006018

Enrollment

300

Registered

2011-07-21

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hyperlipidemia who provide written informed consent

Exclusion criteria

Exclusion criteria: 1) minors 2) Patients with no written informed consent 3) Patients with past history of drug allergy 4) Patients who are inadequate for drug usage 5) Patients with abnormal values of laboratory tests 6) Pregnant women, or nursing women

Design outcomes

Primary

Measure	Time frame
Efficacy and safety of lipid-lowering drugs	—

Countries

Japan

Contacts

Public ContactMinoru Yoshiyama

Osaka City University Graduate School of Medicine Department of Internal medicine and Cardiology

yatakemoto@med.osaka-cu.ac.jp06-6645-3800

Outcome results